AstraZeneca's Imfinzi gets FDA priority review for small cell lung cancer
Share:
(Reuters) - British drugmaker AstraZeneca Plc said on Friday its cancer drug Imfinzi has been granted a speedy review by the U.S. Food and Drug Administration (FDA) for the treatment of a particularly aggressive type of lung cancer.The company said the FDA accepted its supplemental application and granted priority review to Imfinzi for the treatment of previously untreated late-stage small cell lung cancer.A final decision is expected in the first quarter of 2020.